GBIO
Price
$1.03
Change
-$0.06 (-5.50%)
Updated
Dec 18, 04:59 PM (EDT)
64 days until earnings call
INTS
Price
$2.02
Change
+$0.02 (+1.00%)
Updated
Dec 18, 04:59 PM (EDT)
85 days until earnings call
Ad is loading...

GBIO vs INTS

Header iconGBIO vs INTS Comparison
Open Charts GBIO vs INTSBanner chart's image
Generation Bio
Price$1.03
Change-$0.06 (-5.50%)
Volume$2.82K
CapitalizationN/A
Intensity Therapeutics
Price$2.02
Change+$0.02 (+1.00%)
Volume$200
CapitalizationN/A
GBIO vs INTS Comparison Chart
Loading...
GBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GBIO vs. INTS commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GBIO is a Hold and INTS is a Buy.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (GBIO: $1.09 vs. INTS: $2.00)
Brand notoriety: GBIO and INTS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GBIO: 191% vs. INTS: 93%
Market capitalization -- GBIO: $72.8M vs. INTS: $30.21M
GBIO [@Biotechnology] is valued at $72.8M. INTS’s [@Biotechnology] market capitalization is $30.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GBIO’s FA Score shows that 0 FA rating(s) are green whileINTS’s FA Score has 0 green FA rating(s).

  • GBIO’s FA Score: 0 green, 5 red.
  • INTS’s FA Score: 0 green, 5 red.
According to our system of comparison, both GBIO and INTS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GBIO’s TA Score shows that 5 TA indicator(s) are bullish while INTS’s TA Score has 4 bullish TA indicator(s).

  • GBIO’s TA Score: 5 bullish, 3 bearish.
  • INTS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, GBIO is a better buy in the short-term than INTS.

Price Growth

GBIO (@Biotechnology) experienced а -14.84% price change this week, while INTS (@Biotechnology) price change was -22.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

GBIO is expected to report earnings on Feb 20, 2025.

INTS is expected to report earnings on Mar 13, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GBIO($72.8M) has a higher market cap than INTS($30.2M). GBIO YTD gains are higher at: -33.939 vs. INTS (-76.663). INTS has higher annual earnings (EBITDA): -16.26M vs. GBIO (-92.57M). GBIO has more cash in the bank: 185M vs. INTS (2.78M). INTS has less debt than GBIO: INTS (145K) vs GBIO (93.8M). GBIO has higher revenues than INTS: GBIO (18.6M) vs INTS (0).
GBIOINTSGBIO / INTS
Capitalization72.8M30.2M241%
EBITDA-92.57M-16.26M569%
Gain YTD-33.939-76.66344%
P/E RatioN/AN/A-
Revenue18.6M0-
Total Cash185M2.78M6,650%
Total Debt93.8M145K64,690%
TECHNICAL ANALYSIS
Technical Analysis
GBIOINTS
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
57%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
67%
Momentum
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 23 days ago
85%
Bullish Trend 20 days ago
61%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
GBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PGUAX14.83N/A
N/A
Virtus Duff & Phelps Global Infras A
WCMYX10.30-0.01
-0.10%
WCM Quality Dividend Growth Inst
NMIAX28.48-0.11
-0.38%
Columbia Large Cap Enhanced Core A
BPAIX30.80-0.16
-0.52%
Boston Partners All Cap Value Instl
ASVDX10.92-0.77
-6.59%
American Century Small Cap Value R6

GBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, GBIO has been loosely correlated with AURA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GBIO jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GBIO
1D Price
Change %
GBIO100%
-6.03%
AURA - GBIO
48%
Loosely correlated
-2.47%
ATNM - GBIO
46%
Loosely correlated
-3.94%
ABOS - GBIO
46%
Loosely correlated
-0.51%
INZY - GBIO
46%
Loosely correlated
-2.65%
NAUT - GBIO
45%
Loosely correlated
-1.00%
More

INTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, INTS has been loosely correlated with CKPT. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if INTS jumps, then CKPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTS
1D Price
Change %
INTS100%
-1.72%
CKPT - INTS
33%
Loosely correlated
+9.59%
SYRE - INTS
31%
Poorly correlated
+3.44%
MRKR - INTS
30%
Poorly correlated
+17.68%
CARA - INTS
29%
Poorly correlated
-3.22%
GBIO - INTS
28%
Poorly correlated
-6.03%
More